Herbst, R.S. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59 (Suppl. 2), 21–26. [CrossRef] [PubMed]
Roskoski, R., Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharm. Res. 2014, 79, 34–74. [CrossRef] [PubMed]
Liu, H.; Zhang, B.; Sun, Z. Spectrum of EGFR aberrations and potential clinical implications: Insights from integrative pan-cancer analysis. Cancer Commun. 2020, 40, 43–59. [CrossRef] [PubMed]
Sigismund, S.; Avanzato, D.; Lanzetti, L. Emerging functions of the EGFR in cancer. Mol. Oncol. 2018, 12, 3–20. [CrossRef]
Kalyankrishna, S.; Grandis, J.R. Epidermal growth factor receptor biology in head and neck cancer. J. Clin. Oncol. 2006, 24, 2666–2672.
Deric, L.; Wheeler, Y.Y. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease; Humana Press: New York, NY, USA, 2015.
Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006; 3(12): e485. doi:10.1371/journal.pmed.0030485.
Chung, C.H.; Ely, K.; McGavran, L.; Varella-Garcia, M.; Parker, J.; Parker, N.; Jarrett, C.; Carter, J.; Murphy, B.A.; Netterville, J.; et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J. Clin. Oncol. 2006, 24, 4170–4176.
Temam, S.; Kawaguchi, H.; El-Naggar, A.K.; Jelinek, J.; Tang, H.; Liu, D.D.; Lang, W.; Issa, J.P.; Lee, J.J.; Mao, L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J. Clin. Oncol. 2007, 25, 2164–2170.
Zhu, X.; Zhang, F.; Zhang, W.; He, J.; Zhao, Y.; Chen, X. Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-analysis. J. Surg. Oncol. 2013, 108, 387–397.
Licitra, L.; Mesia, R.; Rivera, F.; Remenar, E.; Hitt, R.; Erfan, J.; Rottey, S.; Kawecki, A.; Zabolotnny, D.; Benasso, M.; et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 2011, 22, 1078–1087.
Moon B, Yang SJ, Park SM, Lee SH, Song KS, Jeong EJ, Park M, Kim JS, Yeom YI, Kim JA. LAD1 expression is associated with the metastatic potential of colorectal cancer cells. BMC Cancer. 2020 Dec 2;20(1):1180. doi: 10.1186/s12885-020-07660-0. PMID: 33267790; PMCID: PMC7709356.
Li J, Wang Z, Tie C. High expression of ladinin-1 (LAD1) predicts adverse outcomes: a new candidate docetaxel resistance gene for prostatic cancer (PCa). Bioengineered. 2021 Dec; 12(1): 5749-5759. doi: 10.1080/21655979.2021.1968647. PMID: 34516317; PMCID: PMC8806705.
Klobucar M, Sedic M, Gehrig P, Grossmann J, Bilic M, Kovac-Bilic L, Pavelic K, Kraljevic PS. Basement membrane protein ladinin-1 and the MIF-CD44-beta1 integrin signaling axis are implicated in laryngeal cancer metastasis. Biochim Biophys Acta. 2016; 1862(10): 1938–1954. doi: 10.1016/j.bbadis.2016.07.014.
